| |
Treatment of a patient with genotype 7 HCV infection
with sofosbuvir and velpatasvir
|
| |
| |
Download the PDF here
Hepatology May 2016 advance pub
Jonas Schreiber1, John McNally2, Krishna Chodavarapu2, Evguenia Svarovskaia2, Christophe
Moreno1
1Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Universite Libre de Bruxelles, Brussels, Belgium; Laboratory of experimental Gastroenterology, Universite Libre de Bruxelles, Brussels, Belgium; 2Gilead Sciences, Inc., Foster City, CA, United States.
Ours is the first published case demonstrating that sofosbuvir-velpatasvir can be effective in a patient with genotype 7 infection, and suggests that genotype 7 HCV infected patients may be considered for treatment with sofosbuvir-velpatasvir. This case additionally confirms the pangenotypic activity of sofosbuvir-velpatasvir and suggests that determination of HCV genotype may not be required prior to treatment with this potent DAA combination. Sofosbuvir-velpatasvir has the potential to become an important regimen for treatment of HCV infection in regions of the world where HCV genotyping is expensive, inaccurate, or unavailable. However, in the meantime, it may be advisable for patients originating from Democratic Republic of Congo to be sequenced fully to minimize the risk of misclassifying and subsequently treating patients with a sub-optimal treatment regimen.
|
|
| |
| |
|
|
|
